The U.S. Food and Drug Administration approved Corbus Pharmaceuticals Holdings, Inc.’s proposed registrational study design for its lead oncology candidate CRB‑701 in second‑line head and neck squamous cell carcinoma and cervical cancer, clearing a key regulatory hurdle that enables the company to move forward with Phase 2 expansion cohorts that could support accelerated approval.
CRB‑701 is a next‑generation Nectin‑4 antibody‑drug conjugate that uses a site‑specific, cleavable linker to deliver the cytotoxic payload monomethyl auristatin E (MMAE) directly to tumor cells. The design is intended to improve safety over existing Nectin‑4 ADCs such as Pfizer’s PADCEV, and the FDA’s alignment signals confidence in the platform’s potential to meet unmet medical needs in these indications.
Corbus plans to present updated Phase 1/2 monotherapy data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and expects to report combination data with Keytruda in first‑line HNSCC patients in the fourth quarter of 2026. A registrational study in second‑line HNSCC is slated to begin in mid‑2026, positioning CRB‑701 for a potential market entry after regulatory submission.
The company also announced the departure of Chief Medical Officer Dr. Dominic Smethurst effective June 30 2026 and will add new senior leaders to support the next development phase.
"We're pleased to share this important regulatory update as we continue to progress CRB‑701 as a novel oncology therapeutic to address unmet medical needs for patients. We look forward to sharing updated monotherapy data on CRB‑701 at ASCO and expect to initiate a registrational study for CRB‑701 in second‑line HNSCC in mid‑2026." – Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. "This milestone marks an important transition from clinical proof of concept to pending late‑stage registrational development and the potential for regulatory submission of CRB‑701." – Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.
revised_sentiment_rating
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.